Fig. 2.

b-AP15 sensitizes human tumor cell lines to NK and T cell-mediated killing via TRAIL. a Human tumor cell lines J82, MDA453, HCT116, EST152 and EST027 were treated with 1 μM b-AP15 for 3 h and tested for susceptibility to killing by human NK cells and T cells in an 18 h 51Cr-release assay (n = 3). b J82 cells were treated with b-AP15 [1 μM, 3 h] and tested for killing by NK or T cells in presence of neutralizing antibodies to TRAIL or FasL or in presence of Concanamycin A (CMA) (n = 3, mean ± SEM). The statistical significance was calculated by Student’s paired T test (mean + SEM). *p < 0.05